+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma



Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma



Clinical Cancer Research 13(22 Pt 1): 6689-6695



Angiogenesis is a characteristic of renal cell carcinoma. ABT-510 is an angiogenesis inhibitor that mimics the antiangiogenic properties of thrombospondin-1. This study was designed to assess the safety and efficacy of ABT-510 in patients with advanced renal cell carcinoma. Patients with previously untreated metastatic or unresectable renal cell carcinoma were randomized to treatment with one of two doses of ABT-510, self-administered s.c. twice daily in 28-day treatment periods without intervening rest periods. End points were progression-free survival (PFS), objective response rate, overall survival, and toxicity. The objective response rate was 4% in the 10 mg twice daily group, and there were two unconfirmed PRs in the 100 mg twice daily group. Respective median PFS was 4.2 and 3.3 months, with a 6-month PFS of 39% and 32%. Median overall survival was 27.8 months (10 mg twice daily) and 26.1 months (100 mg twice daily). The most frequent adverse events were injection site reactions (84%), fatigue (50%), headache (20%), and nausea (19%). The incidence of treatment-related, grade 3/4 adverse events was low and included three bleeding episodes (gastrointestinal hemorrhage, intracranial hemorrhage, and hemoptysis) and one thrombotic event (deep vein thrombosis). No deaths were attributed to ABT-510. There was little evidence of clinical activity for ABT-510, and further evaluation as a single agent for treating advanced renal cell carcinoma is not warranted. The evidence of a favorable safety profile may justify further evaluation in combination therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054964607

Download citation: RISBibTeXText

PMID: 18006769

DOI: 10.1158/1078-0432.ccr-07-1477


Related references

Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO). Der Urologe. Ausg. a 54(10): 1443-1445, 2015

A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma. Journal of Clinical Oncology 23(16_Suppl): 4607-4607, 2016

First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO. Der Urologe. Ausg. a 55(9): 1242-1243, 2016

Phase ii study with carboplatin 5 fu in previously untreated patients with advanced squamous cell carcinoma of the head and neck. Journal of Cancer Research & Clinical Oncology 116(Suppl. Part 1): 700, 1990

Phase II study of the EGFR tyrosine kinase erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma. Journal of Clinical Oncology 23(16_Suppl): 7148-7148, 2016

A multicenter phase II study of thalidomide in combination with interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (MRCC). Journal of Clinical Oncology 24(18_Suppl): 14636-14636, 2016

Phase II study of daunorubicin in previously untreated patients with advanced colorectal carcinoma. Medical and Pediatric Oncology 13(1): 30-31, 1985

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investigational new Drugs 31(5): 1283-1293, 2013

Phase ii trial with carboplatin and ifosfamide in previously untreated patients with advanced squamous cell carcinoma of the cervix. Investigational New Drugs 7(4): 428, 1989

High-dose weekly oral leucovorin and 5-fluorouracil in previously untreated patients with advanced colorectal carcinoma: a phase I study. Advances in Experimental Medicine and Biology 244: 167-172, 1988

A phase I study of UFT plus cisplatin in previously untreated patients with advanced non-small cell lung cancer. International Journal of Antimicrobial Agents 17(Suppl. 1): S19, 2001

A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer. ChemoTherapy 61(2): 93-98, 2016

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet. Oncology 13(10): 1055-1062, 2012

Phase II trial of diaziquone in advanced large bowel carcinoma in previously treated and untreated patients: a Southwest Oncology Group Study. Cancer Treatment Reports 69(6): 709-710, 1985

Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology 37(5): 353-357, 2007